Recent Press
Revalia Bio Awarded Up To $26.7 Million ARPA-H Contract Award to Advance Drug Development with Human Data Trials
Revalia will lead the effort to build advanced AI-driven models trained on Human Data Trials, living systems derived from donated human organs, organ-on-chip platforms, and multimodal datasets.
Front-Loading Drug Development: Q&A with Jenna DiRito, PhD, Revalia Bio
Applied Clinical Trials
April 16, 2026
Regulatory setback or scientific signal? The case for human-relevant evidence
pharmaphorum
Mar 26, 2026
How human organs are rewriting the rules of drug development
Drug and Device World
Mar 17, 2026
Meet the Class of 2026 TED Fellows
TED
Mar 3, 2026
Building the Future with America's Frontier Fund
America's Frontier Fund
Mar 3, 2026
Why Data Integrity Is an Ethical Obligation, Not Just a Scientific One
The Scientist
Feb 25, 2026
Revalia Bio's Quest to Replace Animal Models with Human Organs
Inside Precision Medicine
Feb 18, 2026
Beyond animal models: The new FDA human-first drug development framework
Drug and Device World
Nov 19, 2025
Beyond animal testing: How human data trials are reshaping drug development
pharmaphorum
Nov 18, 2025
Jenna DiRito, Co-Founder & COO of Revalia Bio at HLTH2025 with Ian Khan
hlth.
Nov 6, 2025
C-Path Global Impact Conference 2025: Modernizing Clinical Trials: Practical Innovations
Critical Path Institute
Oct 7, 2025
Exclusive: Revalia Bio Raises $14.5M To 'Revolutionize' Drug Development With Human Data Trials
Crunchbase
Sep 4, 2025
Translational AI at the Wyss Institute: how artificial intelligence enables patient impact
Wyss Institute
Jun 26, 2025
National Kidney Foundation invests in health tech company Revalia Bio
Healio
Oct 21, 2024
YSM Faculty Receive Awards for Innovation
Yale School of Medicine
Nov 13, 2024
Forbes' '30 Under 30' 2025 list includes 28 Connecticut connections
CT Insider
Dec 5, 2024
Life sciences company to open headquarters in CT, three other firms to expand presence
CT Insider
Dec 19, 2023